🎉 M&A multiples are live!
Check it out!

LTR Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for LTR Pharma and similar public comparables like Pharming, Galapagos, and Julphar.

LTR Pharma Overview

About LTR Pharma

LTR Pharma Ltd  is a clinical stage pharmaceutical company focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.


Founded

2020

HQ

Australia
Employees

n/a

Website

ltrpharma.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$43.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

LTR Pharma Financials

LTR Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, LTR Pharma achieved revenue of n/a and an EBITDA of -$4.4M.

LTR Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See LTR Pharma valuation multiples based on analyst estimates

LTR Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA n/a -$4.4M XXX XXX XXX
EBITDA Margin NaN% NaN% XXX XXX XXX
Net Profit n/a n/a XXX XXX XXX
Net Margin NaN% NaN% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

LTR Pharma Stock Performance

As of March 14, 2025, LTR Pharma's stock price is AUD 1 (or $0).

LTR Pharma has current market cap of AUD 103M (or $65.2M), and EV of AUD 69.1M (or $43.7M).

See LTR Pharma trading valuation data

LTR Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$43.7M $65.2M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

LTR Pharma Valuation Multiples

As of March 14, 2025, LTR Pharma has market cap of $65.2M and EV of $43.7M.

LTR Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate LTR Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for LTR Pharma and 10K+ public comps

LTR Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $43.7M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -9.9x XXX XXX XXX
P/E -14.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -13.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get LTR Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

LTR Pharma Valuation Multiples

LTR Pharma's NTM/LTM revenue growth is n/a

LTR Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, LTR Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate LTR Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for LTR Pharma and other 10K+ public comps

LTR Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

LTR Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

LTR Pharma M&A and Investment Activity

LTR Pharma acquired  XXX companies to date.

Last acquisition by LTR Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . LTR Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by LTR Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About LTR Pharma

When was LTR Pharma founded? LTR Pharma was founded in 2020.
Where is LTR Pharma headquartered? LTR Pharma is headquartered in Australia.
Is LTR Pharma publicy listed? Yes, LTR Pharma is a public company listed on ASX.
What is the stock symbol of LTR Pharma? LTR Pharma trades under LTP ticker.
When did LTR Pharma go public? LTR Pharma went public in 2023.
Who are competitors of LTR Pharma? Similar companies to LTR Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of LTR Pharma? LTR Pharma's current market cap is $65.2M
Is LTR Pharma profitable? Yes, LTR Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.